Scarica l'app Stockscreener
117.00
1.36%
1.57
Dopo l'orario di chiusura:
117.00
Precedente Chiudi:
$115.43
Aprire:
$116.05
Volume 24 ore:
734.30K
Relative Volume:
0.87
Capitalizzazione di mercato:
$9.73B
Reddito:
$51.48M
Utile/perdita netta:
$-315.00M
Rapporto P/E:
-32.77
EPS:
-3.5708
Flusso di cassa netto:
$-244.00M
1 W Prestazione:
-0.24%
1M Prestazione:
+7.75%
6M Prestazione:
+38.33%
1 anno Prestazione:
+169.09%
Intervallo 1D:
$114.35
$119.63
Intervallo di 1 settimana:
$112.77
$120.67
Portata 52W:
$43.74
$130.05
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Nome
Kymera Therapeutics Inc
Settore
Industria
Telefono
857-285-5314
Indirizzo
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
117.00 | 9.60B | 51.48M | -315.00M | -244.00M | -3.5708 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-05-06 | Iniziato | Canaccord Genuity | Buy |
| 2026-03-16 | Ripresa | Jefferies | Buy |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-06 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-11-03 | Ripresa | Guggenheim | Buy |
| 2025-10-24 | Reiterato | B. Riley Securities | Buy |
| 2025-10-21 | Iniziato | Mizuho | Outperform |
| 2025-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-07-30 | Ripresa | B. Riley Securities | Buy |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-06-03 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-05-20 | Ripresa | Stifel | Buy |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Market Perform |
| 2024-12-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-08-26 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | Iniziato | Oppenheimer | Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-01-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Iniziato | Truist | Buy |
| 2023-05-05 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Iniziato | Raymond James | Mkt Perform |
| 2022-08-15 | Iniziato | Jefferies | Buy |
| 2022-08-03 | Iniziato | Goldman | Buy |
| 2022-07-20 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-03-10 | Iniziato | JP Morgan | Neutral |
| 2022-02-10 | Iniziato | Wells Fargo | Overweight |
| 2021-09-30 | Iniziato | B. Riley Securities | Neutral |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-14 | Iniziato | Berenberg | Buy |
| 2020-12-04 | Iniziato | H.C. Wainwright | Buy |
| 2020-09-15 | Iniziato | BofA Securities | Neutral |
| 2020-09-15 | Iniziato | Cowen | Outperform |
| 2020-09-15 | Iniziato | Guggenheim | Buy |
| 2020-09-15 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Kymera Therapeutics Inc Borsa (KYMR) Ultime notizie
Kymera Therapeutics at citigroup summit: oral immunology push gains pace By Investing.com - Investing.com Canada
KYMR Looks 183.5% Overvalued on GF Value™ Amid Wolfe Research Up - GuruFocus
Squarepoint Ops LLC Raises Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics at Wells Fargo conference: oral pipeline gains pace By Investing.com - Investing.com South Africa
Fund giant T. Rowe Price holds a double-digit stake in Kymera (KYMR) - Stock Titan
Have Kymera Therapeutics Insiders Been Selling Stock? - simplywall.st
KYMR Stock Clocks Best Day In Over 6 Months On Advancing Eczema Trial Timeline - Stocktwits
36,237 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by Legal & General Group Plc - MarketBeat
Kymera Therapeutics chief legal officer Adams disposes of $744k in KYMR stock - Investing.com Nigeria
Kymera Therapeutics (NASDAQ:KYMR) Insider Brian Adams Sells 6,371 Shares of Stock - MarketBeat
Kymera (NASDAQ: KYMR) insider plans stock sale to cover taxes - Stock Titan
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Atlas Venture Life Science Advisors LLC Decreases Stock Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Can KT-621 Mark a Turning Point for Kymera Therapeutics? - The Globe and Mail
Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT) - theglobeandmail.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Braidwell LP Buys 40,604 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
21,058 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Jupiter Topco LLC - MarketBeat
Kymera Therapeutics to Participate in Upcoming September Investor Conferences - Investing News Network
Executive at Kymera Therapeutics (NASDAQ: KYMR) plans another stock sale after June trade of $4.4M - Stock Titan
Five September events will webcast Kymera live - Stock Titan
Man Group plc Makes New $2.19 Million Investment in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses - investingnews.com
A clinical trial testing an oral medicine for eczema has finished enrolling patients. Kymera expects topline data by year-end 2026. - Stock Titan
Kymera Therapeutics (NASDAQ:KYMR) Gains on Higher Price Target - Kalkine Media
KYMR Maintains Buy Rating by Guggenheim -- Price Target Raised t - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Given New $170.00 Price Target at Guggenheim - MarketBeat
Guggenheim raises Kymera Therapeutics price target to $170 on STAT6 program - Investing.com Nigeria
Yiheng Capital Management L.P. Sells 10,000 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
215,588 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Bank of New York Mellon Corp - MarketBeat
Kymera Therapeutics, Inc. $KYMR Shares Sold by Alyeska Investment Group L.P. - MarketBeat
Wellington Management Group LLP Trims Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
119,503 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by The Manufacturers Life Insurance Company - MarketBeat
Freestone Grove Partners LP Purchases New Shares in Kymera Therapeutics, Inc. $KYMR - marketbeat.com
20,000 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by Bamco Inc. NY - MarketBeat
Kymera Therapeutics Inc. (KYMR) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Wells Fargo Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $151 - Moomoo
Wells Fargo & Company Issues Positive Forecast for Kymera Therapeutics (NASDAQ:KYMR) Stock Price - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Buys Shares of 149,908 Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics, Inc. $KYMR Stock Holdings Increased by Odyssean LLC - marketbeat.com
Nicholas Investment Partners LP Invests $6.26 Million in Kymera Therapeutics, Inc. $KYMR - MarketBeat
5,538,210 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by BlackRock Inc. - MarketBeat
Deutsche Bank AG Makes New $12.16 Million Investment in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Piper Sandler Keeps Their Buy Rating on Kymera Therapeutics (KYMR) - The Globe and Mail
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Piper Sandler Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $140 - Moomoo
B of A, Truist raise Kymera Therapeutics price targets - scanx.trade
Eagle Health Investments LP Buys Shares of 166,148 Kymera Therapeutics, Inc. $KYMR - MarketBeat
Merck & Co. Inc. Takes Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
TimesSquare Capital Management LLC Purchases Shares of 157,327 Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics, Inc. $KYMR Shares Sold by Bank of America Corp DE - MarketBeat
Kymera Therapeutics Inc Azioni (KYMR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):